MedTech Dive November 11, 2021
Ricky Zipp

Dexcom’s new G7 CGM system is expected to gain CE mark clearance in Q4, and Insulet’s Omnipod 5 insulin pump is on track for FDA clearance and a limited launch by the end of the year.

Continuous glucose monitor and insulin pump makers continued their 2021 success last quarter while other medtechs were forced to manage through a pandemic spike that dragged third-quarter results.

Dexcom, Tandem Diabetes Care and Insulet grew users and revenues or sales amid the ongoing jump in use of wearables and digital health services. The success for diabetes tech comes as the space still has highly anticipated product launches on the horizon, including Dexcom’s G7 CGM system and Insulet’s Omnipod 5 insulin pump.

Dexcom CEO Kevin...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, Technology, Wearables
Related Articles:
Wearable electrical nerve stimulation device eases long COVID pain and fatigue, say researchers
Singapore tackling chronic diseases with wearables
Researchers use fitness tracker data and machine learning to detect bipolar disorder mood swings
Oura Ring Is ‘Like An Apple Product’ And Could Take Key Health Metric Mainstream
Wearable ultrasound sensor revolutionizes continuous blood pressure monitoring

Share This Article